Data Article

Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases

Thomas U. Schulz\textsuperscript{a}, Sarah Zierold\textsuperscript{a,b}, Michael M. Sachse\textsuperscript{c}, Giulia Pesch\textsuperscript{a}, Dirk Tomsitz\textsuperscript{a}, Katharina Schilbach\textsuperscript{d}, Katharina C. Kähler\textsuperscript{e}, Lars E. French\textsuperscript{a,f}, Lucie Heinzerling\textsuperscript{a,b,g,*}

\textsuperscript{a} Department of Dermatology and Allergy, University Hospital, LMU Munich, Frauenlobstr. 9-11, 80337 Munich, Germany
\textsuperscript{b} Side Effect Registry Immuno-Oncology SERIO, http://www.serio-registry.org, Frauenlobstr. 9-11, 80337 Munich, Germany
\textsuperscript{c} Department of Dermatology, Allergology and Phlebology, Hospital Bremerhaven Reinkenheide, Postbrookstr. 103, 27574 Bremerhaven, Germany
\textsuperscript{d} Medizinische Klinik und Poliklinik IV, LMU Klinikum, Ziemssenstr. 5, 80336 Munich, Germany
\textsuperscript{e} Department of Dermatology, University Hospital Schleswig-Holstein, Arnold-Heller-Str. 3, 24105 Kiel, Germany
\textsuperscript{f} Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, 1295 NW 14th Street, Miami, Florida 33125, USA
\textsuperscript{g} Department of Dermatology, University Hospital Erlangen, Ulmenweg 8, 91054 Erlangen, Germany

DOI of original article: 10.1016/j.ejca.2022.08.029
* Corresponding author.
E-mail address: Lucie.Heinzerling@med.uni-muenchen.de (L. Heinzerling).

https://doi.org/10.1016/j.dib.2022.108676
2352-3409/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ARTICLE INFO

Article history:
Received 6 September 2022
Revised 7 October 2022
Accepted 10 October 2022
Available online 14 October 2022

Dataset link: Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: a large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy (Original data)

Keywords:
Persistent immune-related adverse events (persistent irAEs)
Chronic toxicities
Long-term sequelae
Melanoma
hypothyroidism
Sjogren’s syndrome
Vitiligo
Sarcoidosis

ABSTRACT

This dataset contains demographic, clinical, and health-related quality of life (HRQoL) data from 2905 patients including 200 cancer patients after immune checkpoint inhibitor (ICI) cessation and 2705 patients with a wide variety of autoimmune diseases. Within this multicenter, cross-sectional survey study data were collected questionnaire-based in cancer patients (ICI-patients) ≥ 18 years of age who had received at least one dose of ICI with ≥ 12 weeks since ICI discontinuation. Patients with autoimmune diseases (AI-patients) were ≥ 18 years, had at least one autoimmune disease and had never received ICI. ICI-patients were recruited in three skin cancer centers and via support groups. AI-patients were recruited in an outpatient clinic for internal medicine and via support groups.

Specific questionnaires for ICI-patients/AI-patients were provided paper-based for patients from outpatient clinics and online for patients from support groups. Both questionnaires contained sections with demographic information, clinical data, and the standardized patient-reported outcome measure EuroQol 5D-5L (EQ-5D-5L) to assess HRQoL. Clinical data focused on autoimmunity and therapy of autoimmunity in (1) ICI-patients referring to particularly persistent immune-related adverse events (persistent irAEs) and in (2) AI-patients referring to respective autoimmune diseases. Additionally, specific items on cancer and cancer therapy were included in ICI-patients, and AI-patients were asked about the presence of acute exacerbations of autoimmune diseases. This dataset contains the raw data for ICI-patients and AI-patients, analyzed data on patient demographics, clinical characteristics and HRQoL scores among ICI-patients with/without persistent irAEs and among AI-patients. The data provide a basis for further investigations within the cohort of ICI-patients after ICI cessation and/or for AI-patients with different autoimmune diseases with regard to HRQoL, autoimmunity and therapy of autoimmunity.

© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Specifications Table

| Subject | Immunology |
|---------|------------|
| Specific subject area | Clinical data and health-related quality of life in patients with persistent immune-related adverse events or autoimmune diseases |
| Type of data | Table |
| How the data were acquired | Data were collected using questionnaire-based surveys. Questionnaires comprised the standardized patient-reported outcome measure EuroQol 5D-5L, items on demographic data, and items on clinical data relevant for autoimmunity. |

(continued on next page)
**Value of the Data**

- Data on ICI-patients provide a broad base of cancer survivors after ICI discontinuation for further investigation on clinical parameters and HRQoL.
- Data on AI-patients offer data of numerous autoimmune diseases, related therapies, and implications on HRQoL.
- Researchers in the field of oncology can mainly benefit from the data of ICI-patients as data include a broad sample with relevant parameters.
- Researchers from various medical disciplines may benefit from the data of AI-patients as a broad variety of autoimmune disease is covered.
- The data on ICI-patients give detailed information about persistent/chronic irAEs and related therapies which is – until now – a largely unexplored field.
- The data on AI-patients can be used to investigate specific autoimmune diseases, their impact on HRQoL and their therapies.

1. **Objective**

This dataset was generated to investigate persistent irAEs in cancer patients ≥ 12 weeks after cessation of ICI therapy, to assess the prevalence of persistent irAEs, and to analyze the impact of persistent irAEs on HRQoL [1]. As persistent irAEs mimic non-ICI-induced autoimmune diseases, patients with autoimmune diseases were included in the study to identify commonalities and differences regarding autoimmune symptoms, related therapies, and implications on HRQoL.

2. **Data Description**

The dataset contains demographic data, clinical data and data on HRQoL from 200 ICI-patients and 2705 AI-patients (Table 1) [2].

The distribution of gender and age in the sample of ICI-patients, who mainly had a melanoma with 96.5%, was consistent with the usual distribution among patients with melanoma [3]. The
Table 1
ICI-patients and AI-patients: demographics, clinical characteristics, and recruitment cohorts.

|                         | ICI-patients n = 200 (6.9%) | AI-patients n = 2705 (93.1%) | Total n = 2905 (100.0%) |
|-------------------------|-----------------------------|-----------------------------|------------------------|
| Gender, n (%)           |                             |                             |                        |
| Female                  | 98 (49.0)                   | 2391 (88.4)                 | 2489 (85.7)            |
| Male                    | 102 (51.0)                  | 314 (11.6)                  | 416 (14.3)             |
| Age at time of survey, years |                             |                             |                        |
| Mean (SD)               | 60 (14.6)                   | 47 (11.6)                   | 48 (0.2)               |
| Median (range)          | 60 (23.0-91.0)              | 48 (18.0-84.0)              | 49 (18.0-91.0)         |
| Marital status, n (%)   |                             |                             |                        |
| Partnered               | 152 (76.0)                  | 1989 (73.6)                 | 2141 (73.7)            |
| Not partnered           | 48 (24.0)                   | 716 (26.5)                  | 764 (26.3)             |
| Education, n (%)        |                             |                             |                        |
| Low qualification       | 46 (23.0)                   | 303 (11.2)                  | 349 (12.0)             |
| Middle qualification    | 76 (38.0)                   | 1134 (41.9)                 | 1210 (41.7)            |
| High qualification      | 78 (39.0)                   | 1268 (46.9)                 | 1346 (46.3)            |
| Recruitment cohort, n (%)|                             |                             |                        |
| Outpatient clinics      | 147 (73.5)                  | 9 (0.3)                     | 156 (5.4)              |
| Support groups          | 53 (26.5)                   | 2696 (99.7)                 | 2749 (94.6)            |

ICI, immune checkpoint inhibitor; AI, non-ICI-induced autoimmune disease.

Table 2
ICI-patients (n = 200): types of persistent irAEs.

| Persistent irAEs, n (%) | Outpatient ICI-patients n = 147 (73.5%) | Support group ICI-patients n = 53 (26.5%) | Total ICI-patients n = 200 (100.0%) |
|-------------------------|------------------------------------------|-------------------------------------------|-----------------------------------|
| Patients without persistent irAEs | 86 (58.5) | 14 (26.4) | 100 (50.0) |
| Patients with persistent irAEs | 61 (41.5) | 39 (73.6) | 100 (50.0) |
| Type of persistent irAE, n (%) |
| Arthralgia               | 24 (16.3) | 17 (32.1) | 41 (20.5) |
| Myalgia                  | 20 (13.6) | 18 (34.0) | 38 (19.0) |
| Hypothyroidism           | 16 (10.9) | 20 (37.7) | 36 (18.0) |
| Hypophysitis             | 12 (8.2)  | 3 (5.7)   | 15 (7.5)  |
| Diabetes mellitus        | 2 (1.4)   | 2 (3.8)   | 4 (2.0)   |
| Adrenal insufficiency    | 2 (1.4)   | 2 (3.8)   | 4 (2.0)   |
| Xerostomia               | 12 (8.2)  | 6 (11.3)  | 18 (9.0)  |
| Polyneuropathy           | 3 (2.0)   | 7 (13.2)  | 10 (5.0)  |
| Neuropathy (CN VIII)     | 1 (0.7)   | 0 (0.0)   | 1 (0.5)   |
| Vitiligo                 | 14 (9.5)  | 6 (11.3)  | 20 (10.0) |
| Dermatitis/pruritus      | 4 (2.7)   | 4 (7.5)   | 8 (4.0)   |
| Leukotrichia             | 4 (2.7)   | 4 (7.5)   | 8 (4.0)   |
| Lichen ruber             | 4 (2.7)   | 0 (0.0)   | 4 (2.0)   |
| Pneumonitis/respiratory distress | 7 (4.8) | 9 (17.0) | 16 (8.0) |
| Colitis                  | 5 (3.4)   | 6 (11.3)  | 11 (5.5)  |
| Pancreatitis             | 1 (0.7)   | 1 (1.9)   | 2 (1.0)   |
| Hepatitis                | 1 (0.7)   | 0 (0.0)   | 1 (0.5)   |

* Multiple responses are possible. ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; CN, cranial nerve.

...sample of AI-patients was mainly derived from patients in support groups. AI-patients were more likely to be female, younger, and more highly educated compared to ICI-patients. This is consistent with studies showing that particularly young and educated women take advantage of help in support groups [4,5]. Moreover, the high proportion of female participants in our sample reflects the target group of AI-patients described in literature: approximately 78% of patients affected by autoimmune diseases are women [6]. In particular hormonal and/or genetic factors [7] are responsible for this imbalance and for the about 2.7 higher risk of autoimmune diseases in women compared to men [8].
Table 3
AI-patients (n = 2705): types of autoimmune diseases.

| Type of AI, n (%) | Non-exacerbated AI-patients n = 1837 (67.9%) | Exacerbated AI-patients n = 868 (32.1%) | Total AI-patients n = 2705 (100.0%) |
|------------------|--------------------------------------------|-----------------------------------------|-----------------------------------|
| Addison's disease | 141 (7.7)                                   | 36 (4.1)                                | 177 (6.5)                        |
| Ankylosing spondylitis | 55 (3.0)                                   | 58 (6.7)                                | 113 (4.2)                        |
| Autoimmune gastritis | 9 (0.5)                                    | 3 (0.3)                                 | 12 (0.4)                         |
| Autoimmune hematological disorders | 19 (1.0)                                   | 9 (1.0)                                 | 28 (1.0)                         |
| Autoimmune hepatitis | 69 (3.8)                                    | 23 (2.6)                                | 92 (3.4)                         |
| Autoimmune hyperthyroidism | 132 (7.2)                                 | 41 (4.7)                                | 173 (6.4)                        |
| Autoimmune hypothyroidism | 299 (16.3)                                | 146 (16.8)                              | 445 (16.5)                       |
| Bullous pemphigoid | 2 (0.1)                                     | 3 (0.3)                                 | 5 (0.2)                          |
| Collagenosis (others) | 6 (0.3)                                    | 9 (1.0)                                 | 15 (0.6)                         |
| Crohn's disease | 88 (4.8)                                     | 47 (5.4)                                | 135 (5.0)                        |
| Dermatomyositis | 18 (1.0)                                     | 9 (1.0)                                 | 27 (1.0)                         |
| Diabetes mellitus type 1 | 150 (8.2)                                 | 21 (2.4)                                | 171 (6.3)                        |
| Giant cell arteritis | 5 (0.3)                                     | 2 (0.2)                                 | 7 (0.3)                          |
| Hypophysitis | 14 (0.8)                                     | 4 (0.5)                                 | 18 (0.7)                         |
| Idiopathic pulmonary fibrosis | 4 (0.2)                                  | 5 (0.6)                                 | 9 (0.3)                          |
| Lichen ruber | 40 (2.2)                                     | 31 (3.6)                                | 71 (2.6)                         |
| Lichen sclerosis | 7 (0.4)                                     | 4 (0.5)                                 | 11 (0.4)                         |
| Multiple sclerosis | 49 (2.7)                                     | 17 (2.0)                                | 66 (2.4)                         |
| Myasthenia gravis | 64 (3.5)                                     | 36 (4.1)                                | 100 (3.7)                        |
| Myositis | 28 (1.5)                                     | 18 (2.1)                                | 46 (1.7)                         |
| Neurodermatitis | 29 (1.6)                                     | 12 (1.4)                                | 41 (1.5)                         |
| Pemphigus vulgaris | 17 (0.9)                                     | 6 (0.7)                                 | 23 (0.9)                         |
| Polymyalgia rheumatica | 42 (2.3)                                  | 16 (1.8)                                | 58 (2.1)                         |
| Polymyositis | 26 (1.4)                                     | 16 (1.8)                                | 42 (1.6)                         |
| Polyneuropathy: CIDP | 8 (0.4)                                     | 7 (0.8)                                 | 15 (0.6)                         |
| Polyneuropathy: GBS | 4 (0.2)                                     | 1 (0.1)                                 | 5 (0.2)                          |
| Primary biliary/sclerosing cholangitis | 47 (2.6)                                 | 22 (2.5)                                | 69 (2.6)                         |
| Psoriasis vulgaris | 137 (7.5)                                    | 87 (10.0)                               | 224 (8.3)                        |
| Psoriatic arthritis | 134 (7.3)                                    | 127 (14.6)                              | 261 (9.6)                        |
| Rheumatoid arthritis | 107 (5.8)                                   | 94 (10.8)                               | 201 (7.4)                        |
| Sarcoidosis | 185 (10.1)                                   | 85 (9.8)                                | 270 (10.0)                       |
| Sjogren's syndrome | 215 (11.7)                                  | 154 (17.7)                              | 369 (13.6)                       |
| Systemic sclerosis | 66 (3.6)                                     | 50 (5.8)                                | 116 (4.3)                        |
| Systemic lupus erythematosus | 181 (9.9)                                 | 78 (9.0)                                | 259 (9.6)                        |
| Ulcerative colitis | 79 (4.3)                                     | 48 (5.5)                                | 127 (4.7)                        |
| Vasculitis (others) | 68 (3.7)                                     | 38 (4.4)                                | 106 (3.9)                        |
| Vitiligo | 204 (11.1)                                   | 74 (8.5)                                | 278 (10.3)                       |

* Multiple responses are possible. AI, non-ICI-induced autoimmune disease; CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barré syndrome.

The data shows persistent irAEs in 41.5% of ICI-patients (Table 2) and a broad variety of autoimmune-diseases in AI-patients (Table 3).

All patients filled the EQ-5D-5L to assess HRQoL. The EQ-5D-5L includes five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) rated by five ordinal levels (no, slight, moderate, severe, or extreme problems). Based on the ratings and on a value set for the German population, the EQ-Index score was determined for each patient. The EQ-Index score ranks on a scale from -0.661 (extreme problems in all five dimensions) to 1 (no problems in any dimension). Moreover, the EQ-5D-5L comprises a visual analogue scale indicating subjective HRQoL on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) which corresponds to the EQ-VAS score.

To evaluate internal consistency of EQ-Index scores and EQ-VAS scores in ICI-patients and in AI-patients respectively, standardized Cronbach’s alpha was calculated for each group showing good internal consistency among ICI-patients (0.751) as well as among AI-patients (0.742) [9].
The dataset comprises the following files, available on Mendeley Data [2]:

- **1. Questionnaires**: This file contains the questionnaire for ICI-patients after immunotherapy and the questionnaire for AI-patients with autoimmune diseases in English.
- **2. Data_AI-patients**: This file contains the raw data of the survey among AI-patients extended by a legend. Raised data comprised recruitment, case, gender, age, education, marital status, onset of autoimmune disease, state of exacerbation, type of autoimmune disease and related burden, therapy of autoimmune disease and related burden, EQ-5D-5L dimensions, EQ-Index score, and EQ-VAS score.
- **2. Data_ICI-patients**: This file contains the raw data of the survey among ICI-patients extended by a legend. Raised data comprised recruitment, case, gender, age, education, cancer type, cancer stage, metastatic status, response to therapy, type of ICIs administered, time since last ICI dose, burden before/during/after ICI, reversible irAEs, therapy of reversible irAEs, persistent irAEs, burden of persistent irAEs, therapy of persistent irAEs, burden of therapy of persistent irAEs, EQ-5D-5L dimensions, EQ-Index score, EQ-VAS score, patients’ retrospective evaluation of ICI therapy, previous cancer therapies, and current cancer therapies.
- **3. AI-Patients_demographics & clinical characteristics**: This file contains analyzed demographics and clinical characteristics of AI-patients as total and divided by exacerbation status.
- **3. ICI-Patients_demographics & clinical characteristics**: This file contains analyzed demographics and clinical characteristics of ICI-patients as total and divided by recruitment type.
- **4. Autoimmunity_HRQoL and burden**: This file contains EQ-Index scores, EQ-VAS scores, burden of symptoms and burden of therapies in ICI-patients/AI-patients with persistent irAEs/autoimmune diseases divided by recruitment cohort/exacerbation status.

### 3. Experimental Design, Materials and Methods

After obtaining approval from the ethics committee (LMU Munich; 21-0499 KB), this multicenter cross-sectional study was conducted from April to October 2021.

ICI-patients were recruited at three outpatient clinics of skin cancer centers (Department of Dermatology and Allergy, LMU Klinikum in Munich; Department of Dermatology, University Hospital Schleswig-Holstein in Kiel; Department of Dermatology, Allergology and Phlebolgy, Hospital Bremerhaven-Reinkenheide in Bremerhaven) by weekly review of outpatient lists. In parallel, support groups for cancer patients were contacted and asked to forward an online link to their members. The same procedure was used to recruit AI-patients, except that an internal medicine outpatient clinic (Department of Internal Medicine IV, LMU Klinikum in Munich) recruited the patients and support groups for patients with a wide variety of autoimmune diseases were contacted. Questionnaires in outpatient clinics were paper-based and questionnaires in support groups were conducted using an online survey tool. Patients in the outpatient clinics had the option of handing in the paper-based questionnaires with a prepaid envelope or via an on-site drop-off box. Eligible ICI-patients were ≥ 18 years of age, had received at least one dose of ICI with the last dose ≥ 12 weeks ago. Eligible AI-patients were ≥ 18 years of age, had at least one autoimmune disease and had never received any ICI before. Participation in this study was voluntary for all respondents. Participants were informed at the beginning of the survey that all data would be collected, analyzed, and published anonymously.

Specific questionnaires were created for ICI-patients and AI-patients, with certain sections of the questionnaires resembling each other. To detect misconceptions and reduce measurement errors, the questionnaires were pretested on selected groups of participants and revised accordingly. Both questionnaires included sections with demographic information (gender, age, highest educational level, and marital status) and the standardized patient-reported outcome measure EQ-5D-5L to assess HRQoL [10] after obtaining permission from EuroQol Group.
(1) Additionally, ICI-questionnaires recorded the following self-reported data: type of cancer, metastatic status, previous ICI therapy, date of last ICI administration, burden of cancer before/during/after ICI therapy indicated on a VAS from 0 (not at all) to 100 (very much), reversible irAEs, therapy of reversible irAEs, persistent irAEs as well as their burden within the last week indicated on a VAS from 0 (not at all) to 100 (very much), therapy of persistent irAEs as well as its burden within the last week indicated on a VAS from 0 (not at all) to 100 (very much), and the assessment of ICI therapy and patient education, respectively indicated on a VAS from 0 (I don't agree) to 100 (I agree). Before issuing ICI-questionnaires to patients in outpatient clinics, physicians completed a section on type of cancer, current stage of cancer, previous drug-based anti-cancer therapies, current drug-based anti-cancer therapies, and date of last ICI administration. For patients reached via support groups, this section was omitted and supplemented with a question about current cancer stage and current drug-based anti-cancer therapy.

(2) AI-questionnaires contained further self-reported information on type of autoimmune disease as well as burden of autoimmunity within the last week indicated on a VAS from 0 (not at all) to 100 (very much), onset of autoimmune disease, presence of acute exacerbation, and therapy of autoimmune disease) as well as its burden within the last week indicated on a VAS from 0 (not at all) to 100 (very much).

All collected questionnaires were entered into a data set and merged. If values were missing or inclusion criteria were not met, the entire case was deleted from the data set. Nominal, ordinal and metric variables were summarized by means, medians and/or percentages. Standardized Cronbach’s alpha was calculated for EQ-Index scores and EQ-VAS scores among ICI-patients and AI-patients respectively. Statistical analyses were conducted using SPSS Statistics (IBM®, version 28.0).

Ethics Statements

The Ethics Committee at the Medical Faculty of LMU Munich approved the clinical study as anonymized collection and analysis of patient data (21-0499 KB). Informed consent has been obtained from all participants. The research has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

CRediT Author Statement

**Thomas U. Schulz**: Conceptualization, Methodology, Formal analysis, Investigation, Data Curation, Writing – original draft, Writing – review & editing. **Sarah Zierold**: Conceptualization, Investigation, Writing – review & editing. **Michael M. Sachse**: Investigation, Writing – review & editing. **Giulia Pesch**: Investigation, Writing – review & editing. **Dirk Tomsitz**: Investigation, Writing – review & editing. **Katharina Schilbach**: Investigation, Writing – review & editing. **Katharina C. Köhler**: Investigation, Writing – review & editing. **Lars E. French**: Investigation, Writing – review & editing. **Lucie Heinzerling**: Conceptualization, Methodology, Investigation, Writing – review & editing, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S. Zierold has received speaker fees and/or travel grants from BMS, Sun Pharma and MSD. M. M. Sachse reports speaker honoraria from Novartis and advisory board honoraria from Sanofi Genzyme. D. Tomsitz reports consultancy, speaker fees
and/or travel grants from BMS, Roche, Novartis, Sanofi, Recordati, Kyowa Kirin and Sun Pharma. K. Schilbach has served as consultant and/or has received honoraria from Recordati rare diseases, Pfizer, Ipsen, Sandoz and Consilient Health. There are no conflicts of interest concerning the present study. K. C. Kähler has served as consultant and/or has received honoraria from Amgen, Roche, Bristol Myers Squibb, Merck Sharp and Dohme, Pierre Fabre and Novartis; travel support from Amgen, Merck Sharp and Dohme, Bristol Myers Squibb, Amgen, Pierre Fabre, Medac and Novartis. L. E. French has served as paid consultant and/or speaker for Galderma, Janssen, Leo Pharma, Eli Lilly, Almirall, Union Therapeutics, Regeneron, Novartis, Amgen, Abbvie, UCB, Biotest, AC-Immune and InflaRx. None of these activities pertain to cancer immunotherapy and ICIs however. L. Heinzerling reports consultancy, speaker fees, travel grants and/or research funding: BMS, MSD, Merck, Roche, Amgen, Curevac, Novartis, Sanofi and Pierre Fabre; clinical studies: BMS, MSD, Merck, Roche, Amgen, GSK, Curevac and Novartis. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data Availability

Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: a large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy (Original data) (Mendeley Data).

Acknowledgments

The authors would like to thank the patients for participating in this study.

Funding: This work was supported by the German Federal Ministry of Education and Research (BMBF) as part of the project MelAutim [grant number 01ZX1905A].

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dib.2022.108676.

References

[1] T.U. Schulz, S. Zierold, M.M. Sachse, G. Pesch, D. Tomsitz, K. Schilbach, K.C. Kähler, L.E. French, L. Heinzerling, Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients’ health-related quality of life, Eur. J. Cancer. 176 (2022) 88–99, doi:10.1016/j.ejca.2022.08.029.
[2] T.U. Schulz, S. Zierold, M.M. Sachse, G. Pesch, D. Tomsitz, K. Schilbach, K.C. Kähler, L.E. French, L. Heinzerling, Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: a large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseases, Mendeley Data, V2 (2022), doi:10.17632/jvs782kvw8.2.
[3] A. Joosse, E. de Vries, R. Eckel, T. Nijsten, A.M. Eggermont, D. Hölzel, J.W. Coebergh, J. Engel, Gender differences in melanoma survival: female patients have a decreased risk of metastasis, J. Invest. Dermatol. 131 (3) (2011) 719–726, doi:10.1038/jid.2010.354.
[4] G.E. Grande, L.B. Myers, S.R. Sutton, How do patients who participate in cancer support groups differ from those who do not? Psychooncology 15 (4) (2006) 321–334, doi:10.1002/pon.956.
[5] S.K. Steginga, A. Campbell, M. Ferguson, A. Beeden, M. Walls, W. Cairns, J. Dunn, Socio-demographic, psychosocial and attitudinal predictors of help seeking after cancer diagnosis, Psychooncology 17 (10) (2008) 997–1005, doi:10.1002/pon.1317.
[6] D. Fairweather, P. Frisancho-Kiss, N.R. Rose, Sex differences in autoimmune disease from a pathological perspective, Am. J. Pathol. 173 (3) (2008) 600–609, doi:10.2353/ajpath.2008.071008.
[7] O.L. Quintero, M.J. Amador-Patarroyo, G. Montoya-Ortiz, A. Rojas-Villarraga, J.M. Anaya, Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity, J. Autoimmun. 38 (2-3) (2012) J109–J119, doi:10.1016/j.jaut.2011.10.003.
[8] D.L. Jacobson, S.J. Gange, N.R. Rose, N.M. Graham, Epidemiology and estimated population burden of selected autoimmune diseases in the United States, Clin. Immunol. Immunopathol. 84 (3) (1997) 223–243, doi:10.1006/clin.1997.4412.

[9] D.L. Streiner, Starting at the beginning: an introduction to coefficient alpha and internal consistency, J. Pers. Assess. 80 (1) (2003) 99–103, doi:10.1207/S15327752JPA8001_18.

[10] M. Herdman, C. Gudex, A. Lloyd, M. Janssen, P. Kind, D. Parkin, G. Bonsel, X. Badia, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual. Life. Res. 20 (10) (2011) 1727–1736, doi:10.1007/s11136-011-9903-x.